Depomed Inc. Sets New 1-Year High at $11.02 (DEPO)
Depomed (NASDAQ:DEPO) set a new 52-week high during trading hours on Friday, Stock Ratings Network.com reports. The company traded as high as $11.02 and last traded at $10.98, with a volume of 437,865 shares. The stock had previously closed at $10.58.
Several analysts have recently commented on the stock. Analysts at JMP Securities raised their price target on shares of Depomed from $10.00 to $11.00 in a research note to investors on Wednesday, December 18th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of Depomed from $9.00 to $11.00 in a research note to investors on Friday, November 22nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Depomed has a consensus rating of “Buy” and a consensus target price of $10.00.
Depomed has a one year low of $4.99 and a one year high of $10.77. The stock has a 50-day moving average of $8.92 and a 200-day moving average of $7.37. The company’s market cap is $619.4 million.
Depomed (NASDAQ:DEPO) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.04. The company had revenue of $37.50 million for the quarter, compared to the consensus estimate of $35.55 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis.
Depomed, Inc (NASDAQ:DEPO) is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.